MDXH Share Price Performance
€0
0.00 (0.00%)
Price €0
Fair Value€7.70
Share Pricen/a
MDxHealth SA Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
MDXH Community Narratives
AN
Fair Value €7.7 60.8% undervalued intrinsic discount
Urology Diagnostics Expansion And Liquid Testing Shift Will Drive Long-Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Urology Diagnostics Expansion And Liquid Testing Shift Will Drive Long-Term Earnings Power
Catalysts About MDxHealth MDxHealth provides precision molecular diagnostics that guide urology clinicians and patients through the full prostate cancer diagnostic pathway. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€7.7
60.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
19% p.a.
Profit Margin
33.55%
Future PE
7.54x
Price in 2026
€9.2
Trending Discussion
Recently Updated Narratives
AN
Urology Diagnostics Expansion And Liquid Testing Shift Will Drive Long-Term Earnings Power
Fair Value: €7.7 60.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MDxHealth SA Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
n/a
- -1.64
- 60.42%
- -70.37%
- 201.8%
About MDXH
- Founded
- 2003
- Employees
- 255
- CEO
- WebsiteView website
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
